FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016019393> ?p ?o ?g. }

• W2016019393 endingPage "701" @default.
• W2016019393 startingPage "693" @default.
• W2016019393 abstract "Summary Low doses of the humanized anti‐ CD 20 monoclonal antibody, veltuzumab, were evaluated in 41 patients with immune thrombocytopenia ( ITP ), including 9 with ITP ≤1 year duration previously treated with steroids and/or immunoglobulins, and 32 with ITP >1 year and additional prior therapies. They received two doses of 80–320 mg veltuzumab 2 weeks apart, initially by intravenous ( IV ) infusion (N = 7), or later by subcutaneous ( SC ) injections (N = 34), with only one Grade 3 infusion reaction and no other safety issues. Thirty‐eight response‐assessable patients had 21 (55%) objective responses (platelet count ≥30 × 10 9 /l and ≥2 × baseline), including 11 (29%) complete responses ( CR s) (platelet count ≥100 × 10 9 /l). Responses (including CR s) occurred with both IV and SC administration, at all veltuzumab dose levels, and regardless of ITP duration. Responders with ITP ≤1 year had a longer median time to relapse (14·4 months) than those with ITP >1 year (5·8 months). Three patients have maintained a response for up to 4·3 years. SC injections resulted in delayed and lower peak serum levels of veltuzumab, but B‐cell depletion occurred after first administration even at the lowest doses. Eight patients, including 6 responders, developed anti‐veltuzumab antibodies following treatment (human anti‐veltuzumab antibody, 19·5%). Low‐dose SC veltuzumab appears convenient, well‐tolerated, and with promising clinical activity in relapsed ITP .( Clinicaltrials.gov identifier: NCT00547066.)" @default.
• W2016019393 created "2016-06-24" @default.
• W2016019393 creator A5003890903 @default.
• W2016019393 creator A5014083764 @default.
• W2016019393 creator A5031962740 @default.
• W2016019393 creator A5033036057 @default.
• W2016019393 creator A5062688748 @default.
• W2016019393 creator A5062795249 @default.
• W2016019393 creator A5087541775 @default.
• W2016019393 date "2013-07-06" @default.
• W2016019393 modified "2023-10-18" @default.
• W2016019393 title "Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study" @default.
• W2016019393 cites W1964034932 @default.
• W2016019393 cites W1970794592 @default.
• W2016019393 cites W1971099007 @default.
• W2016019393 cites W1976668348 @default.
• W2016019393 cites W1980002878 @default.
• W2016019393 cites W1984073642 @default.
• W2016019393 cites W1986085903 @default.
• W2016019393 cites W1989118573 @default.
• W2016019393 cites W1991437102 @default.
• W2016019393 cites W2009389738 @default.
• W2016019393 cites W2013946336 @default.
• W2016019393 cites W2019710876 @default.
• W2016019393 cites W2029951657 @default.
• W2016019393 cites W2032681307 @default.
• W2016019393 cites W2042239736 @default.
• W2016019393 cites W2052970048 @default.
• W2016019393 cites W2054268831 @default.
• W2016019393 cites W2058605959 @default.
• W2016019393 cites W2059190713 @default.
• W2016019393 cites W2065239231 @default.
• W2016019393 cites W2080352981 @default.
• W2016019393 cites W2084718852 @default.
• W2016019393 cites W2085752173 @default.
• W2016019393 cites W2088182580 @default.
• W2016019393 cites W2089627066 @default.
• W2016019393 cites W2107586631 @default.
• W2016019393 cites W2119920607 @default.
• W2016019393 cites W2134264204 @default.
• W2016019393 cites W2142115110 @default.
• W2016019393 cites W2149065814 @default.
• W2016019393 cites W2607514063 @default.
• W2016019393 cites W2801927229 @default.
• W2016019393 cites W4232025330 @default.
• W2016019393 doi "https://doi.org/10.1111/bjh.12448" @default.
• W2016019393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23829485" @default.
• W2016019393 hasPublicationYear "2013" @default.
• W2016019393 type Work @default.
• W2016019393 sameAs 2016019393 @default.
• W2016019393 citedByCount "24" @default.
• W2016019393 countsByYear W20160193932013 @default.
• W2016019393 countsByYear W20160193932014 @default.
• W2016019393 countsByYear W20160193932016 @default.
• W2016019393 countsByYear W20160193932017 @default.
• W2016019393 countsByYear W20160193932018 @default.
• W2016019393 countsByYear W20160193932019 @default.
• W2016019393 countsByYear W20160193932021 @default.
• W2016019393 countsByYear W20160193932022 @default.
• W2016019393 countsByYear W20160193932023 @default.
• W2016019393 crossrefType "journal-article" @default.
• W2016019393 hasAuthorship W2016019393A5003890903 @default.
• W2016019393 hasAuthorship W2016019393A5014083764 @default.
• W2016019393 hasAuthorship W2016019393A5031962740 @default.
• W2016019393 hasAuthorship W2016019393A5033036057 @default.
• W2016019393 hasAuthorship W2016019393A5062688748 @default.
• W2016019393 hasAuthorship W2016019393A5062795249 @default.
• W2016019393 hasAuthorship W2016019393A5087541775 @default.
• W2016019393 hasBestOaLocation W20160193931 @default.
• W2016019393 hasConcept C121332964 @default.
• W2016019393 hasConcept C126322002 @default.
• W2016019393 hasConcept C142424586 @default.
• W2016019393 hasConcept C159654299 @default.
• W2016019393 hasConcept C197934379 @default.
• W2016019393 hasConcept C203014093 @default.
• W2016019393 hasConcept C71924100 @default.
• W2016019393 hasConcept C87355193 @default.
• W2016019393 hasConcept C89560881 @default.
• W2016019393 hasConcept C90924648 @default.
• W2016019393 hasConceptScore W2016019393C121332964 @default.
• W2016019393 hasConceptScore W2016019393C126322002 @default.
• W2016019393 hasConceptScore W2016019393C142424586 @default.
• W2016019393 hasConceptScore W2016019393C159654299 @default.
• W2016019393 hasConceptScore W2016019393C197934379 @default.
• W2016019393 hasConceptScore W2016019393C203014093 @default.
• W2016019393 hasConceptScore W2016019393C71924100 @default.
• W2016019393 hasConceptScore W2016019393C87355193 @default.
• W2016019393 hasConceptScore W2016019393C89560881 @default.
• W2016019393 hasConceptScore W2016019393C90924648 @default.
• W2016019393 hasIssue "5" @default.
• W2016019393 hasLocation W20160193931 @default.
• W2016019393 hasLocation W20160193932 @default.
• W2016019393 hasOpenAccess W2016019393 @default.
• W2016019393 hasPrimaryLocation W20160193931 @default.
• W2016019393 hasRelatedWork W13788639 @default.
• W2016019393 hasRelatedWork W1982913438 @default.
• W2016019393 hasRelatedWork W1998274488 @default.
• W2016019393 hasRelatedWork W2060315896 @default.

• next